Pangea Pharamaceuticals

Pangea Pharmaceuticals Advances Its Next Phase of Growth With an Expanding Commercial Portfolio

7/7/2026 7:25pm 467

Growing portfolio, strategic partnerships, and enhanced capabilities position the company to bring differentiated therapies to market and address longstanding gaps in patient care FORT LAUDERDALE, Fla. — (BUSINESS WIRE) — Pangea Pharmaceuticals, a U.S.-based, patient-centered pharmaceutical company focused on bringing differentiated, clinically relevant products to market, today announced the next phase of its growth strategy, […]

Pangea Pharmaceuticals Announces U.S. Launch of Sdamlo™, the First and Only FDA-Approved, Amlodipine Powder for Oral Solution

4/17/2026 12:02pm 436

Unit-dose, alcohol-free formulation designed to support precise dosing and ease of administration across pediatric, geriatric, dysphagic, and institutional care settings [Fort Lauderdale, FL] — [March Day, 2026] — Pangea Pharmaceuticals, a U.S.-based, patient-centered pharmaceutical company focused on bringing differentiated, clinically relevant products to market, today announced the U.S. launch of Sdamlo™ (amlodipine for oral solution), […]

Pangea Pharmaceuticals Partners with Brillian Pharma to Commercialize Sdamlo™ — A First-of-Its-Kind, Novel, Alcohol-Free, Easy-to-administer Amlodipine Oral Solution

1/16/2026 5:03pm 1,248

Pangea Pharmaceuticals, a U.S.-based pharmaceutical company focused on delivering differentiated, clinically relevant therapies, today announced a strategic commercial partnership with Brillian Pharma, granting Pangea exclusive U.S. commercialization rights to Sdamlo™ (Amlodipine Besylate), NDA 219531, across all approved strengths. The commercial launch and more information will be announced in Q1 2026. Amlodipine is one of the […]

Pangea @ CPHI Frankfurt 2025

10/29/2025 1:59pm 421

CPHI Worldwide 2025 in Frankfurt, Germany is the world’s largest pharmaceutical event, uniting industry leaders, innovators, and experts across the pharmaceutical industry world-wide. For Pangea, CPHI Frankfurt is an inspiring reminder of why collaboration and innovation are at the heart of what we do at Pangea Pharmaceuticals. Our mission is to bridge science and accessibility […]

Pangea Pharmaceuticals Launches Bucapsol™ (buspirone HCl) Oral Capsules: A Next-Generation Anxiolytic for Clarity, Control, and Confidence

7/17/2025 8:00am 2,154

Clinically proven to treat Generalized Anxiety Disorder (GAD), Bucapsol™ (buspirone HCl) delivers effective, sustained symptom relief without sedation, cognitive dulling, or risk of dependency—empowering patients to stay functional, focused, and in control. FORT LAUDERDALE, FL — July 17, 2025 — Pangea Pharmaceuticals is pleased to announce the nationwide launch of Bucapsol™ (buspirone HCl) Oral Capsules, […]

Pangea Pharmaceuticals Celebrates Strong Momentum Following Reintroduction of Ergomar® Sublingual Tablets in the U.S.

6/12/2025 2:04pm 433

Pangea Pharmaceuticals Expands Access to Ergomar® Sublingual Tablets, Reinforcing Commitment to Patients and Providers. FORT LAUDERDALE, FL — June 10, 2025 — Pangea Pharmaceuticals is pleased to share continued momentum and expanded access for Ergomar® Sublingual Tablets (2 mg; Ergotamine Tartrate, USP; ANDA 087693), a unique migraine and cluster headache therapy that has gained significant traction since […]

A New Era in Healthcare

4/15/2025 12:00pm 741

Bridging Tradition and Forward-Thinking Solutions to Shape the Future of Healthcare Pangea Pharmaceuticals, a dynamic and forward-thinking pharmaceutical company, is reshaping the healthcare landscape with its innovative approach to drug development, distribution, and patient access. Founded in 2018 by industry veterans Anthony LaViola (CEO) and Steve Flood (President), Pangea Pharmaceuticals combines cutting-edge pharmaceutical solutions with […]